Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomea Fusion Inc
(NQ:
BMEA
)
7.610
+0.730 (+10.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomea Fusion Inc
< Previous
1
2
3
4
5
6
7
Next >
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
December 11, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 11, 2023
Via
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
14 Analysts Have This to Say About Biomea Fusion
July 25, 2023
Via
Benzinga
Why Biomea Fusion Stock Is Falling Today?
July 24, 2023
Biomea Fusion Inc (NASDAQ: BMEA) released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with
Via
Benzinga
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
December 09, 2023
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 08, 2023
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.
Via
Benzinga
Why Is Cancers/Metabolic Diseases-Focused Biomea Fusion Stock Trading Lower Today?
December 08, 2023
Biomea Fusion Inc (NASDAQ: BMEA) announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase 2...
Via
Benzinga
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin
December 08, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
December 07, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular
December 07, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
December 05, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 04, 2023
Via
Benzinga
SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday
December 04, 2023
U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 29, 2023
Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 29, 2023
Via
Benzinga
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
November 29, 2023
Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 29, 2023
Via
Benzinga
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
November 27, 2023
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
November 16, 2023
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetes
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
November 08, 2023
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
November 02, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
October 30, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
October 17, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
October 05, 2023
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
September 28, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
August 31, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
July 31, 2023
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 24, 2023
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.